| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
122,273 |
85,129 |
$9.10M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
160,239 |
116,779 |
$7.48M |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
35,520 |
26,343 |
$3.05M |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
34,222 |
25,131 |
$2.67M |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
30,233 |
21,789 |
$2.21M |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
84,797 |
63,031 |
$2.06M |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
18,052 |
12,489 |
$1.36M |
| 90461 |
|
48,421 |
34,035 |
$983K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
9,284 |
8,312 |
$256K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
22,509 |
13,332 |
$184K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
79,772 |
57,348 |
$108K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
21,137 |
12,651 |
$95K |
| 99188 |
|
21,233 |
16,183 |
$82K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
26,641 |
19,279 |
$80K |
| 99460 |
|
822 |
719 |
$43K |
| 99051 |
|
21,228 |
15,971 |
$43K |
| 99238 |
Hospital discharge day management, 30 minutes or less |
706 |
622 |
$30K |
| 83655 |
|
11,739 |
8,422 |
$29K |
| 87428 |
|
5,254 |
2,709 |
$28K |
| 90686 |
|
9,076 |
8,009 |
$22K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
2,950 |
2,300 |
$22K |
| 90670 |
|
18,239 |
13,792 |
$20K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
9,415 |
6,677 |
$18K |
| 81002 |
|
40,962 |
29,707 |
$17K |
| 87807 |
|
5,453 |
4,048 |
$15K |
| G2211 |
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) |
24,171 |
13,990 |
$15K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
1,154 |
654 |
$13K |
| 90677 |
|
2,745 |
1,720 |
$12K |
| 90633 |
|
12,546 |
9,197 |
$11K |
| 90647 |
|
15,119 |
11,054 |
$9K |
| 99080 |
|
573 |
547 |
$8K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
6,922 |
6,389 |
$7K |
| 99072 |
|
20,250 |
18,128 |
$6K |
| 99383 |
|
50 |
41 |
$5K |
| 90696 |
|
2,952 |
1,878 |
$4K |
| 99381 |
|
63 |
60 |
$4K |
| 90710 |
|
3,349 |
2,063 |
$4K |
| 92551 |
|
66,349 |
46,974 |
$4K |
| 90681 |
|
5,958 |
4,346 |
$4K |
| 90651 |
|
8,685 |
5,628 |
$3K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
233 |
192 |
$3K |
| 90688 |
|
1,447 |
1,261 |
$3K |
| 0072A |
|
318 |
157 |
$3K |
| 99384 |
|
42 |
25 |
$2K |
| 94664 |
|
784 |
643 |
$2K |
| 90723 |
|
15,144 |
11,393 |
$2K |
| 90707 |
|
2,070 |
1,709 |
$2K |
| 0071A |
|
203 |
171 |
$2K |
| 90472 |
Immunization administration, each additional vaccine (list separately) |
112 |
103 |
$1K |
| 90700 |
|
1,326 |
1,006 |
$1K |
| 90715 |
|
3,506 |
2,246 |
$964.74 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
996 |
855 |
$943.92 |
| 86318 |
|
335 |
188 |
$877.35 |
| 99382 |
|
67 |
24 |
$848.64 |
| 0001A |
|
145 |
145 |
$668.25 |
| 90620 |
|
1,255 |
840 |
$558.63 |
| 91300 |
|
135 |
120 |
$545.73 |
| 90716 |
|
2,326 |
1,851 |
$512.59 |
| 99173 |
|
69,920 |
49,678 |
$242.33 |
| 90734 |
|
6,518 |
4,232 |
$220.74 |
| 0002A |
|
134 |
134 |
$192.00 |
| 69210 |
|
135 |
100 |
$139.76 |
| 82948 |
|
338 |
108 |
$130.97 |
| 81025 |
|
77 |
71 |
$116.48 |
| 96161 |
|
321 |
274 |
$77.52 |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
12 |
12 |
$35.25 |
| 90685 |
|
12 |
12 |
$24.01 |
| 96127 |
|
561 |
535 |
$17.88 |
| 85018 |
|
497 |
484 |
$4.29 |
| 90648 |
|
50 |
47 |
$0.00 |
| 90661 |
|
19 |
19 |
$0.00 |
| 80061 |
Lipid panel |
16 |
16 |
$0.00 |
| G8431 |
Screening for depression is documented as being positive and a follow-up plan is documented |
13 |
12 |
$0.00 |
| 90656 |
|
81 |
80 |
$0.00 |
| 84443 |
Thyroid stimulating hormone (TSH) |
15 |
15 |
$0.00 |
| 92567 |
|
166 |
140 |
$0.00 |
| 36416 |
|
153 |
148 |
$0.00 |
| 91307 |
|
243 |
154 |
$0.00 |
| G8510 |
Screening for depression is documented as negative, a follow-up plan is not required |
213 |
189 |
$0.00 |
| 91305 |
|
101 |
30 |
$0.00 |